Erratum: High-throughput Phenotyping of Lung Cancer Somatic Mutations (Cancer Cell (2016) 30(2) (214–228) (S1535610816302823) (10.1016/j.ccell.2016.06.022));High-throughput Phenotyping of Lung Cancer Somatic Mutations

Cancer Cell

Volumn 30, Issue 2, 2016, Pages 214-228

  Berger, Alice H ^a,b,c   Brooks, Angela N ^a,b,c,f   Wu, Xiaoyun ^b   Shrestha, Yashaswi ^b   Chouinard, Candace ^b   Piccioni, Federica ^b   Bagul, Mukta ^b   Kamburov, Atanas ^b,c,d   Imielinski, Marcin ^a,b,c   Hogstrom, Larson ^b   Zhu, Cong ^b   Yang, Xiaoping ^b   Pantel, Sasha ^b   Sakai, Ryo ^e   Watson, Jacqueline ^a,b   Kaplan, Nathan ^a   Campbell, Joshua D ^a,b,c   Singh, Shantanu ^b   Root, David E ^b   Narayan, Rajiv ^b   Natoli, Ted ^b   Lahr, David L ^b   Tirosh, Itay ^b   Tamayo, Pablo ^b   Getz, Gad ^b,c,d   Wong, Bang ^b   Doench, John ^b   Subramanian, Aravind ^b   Golub, Todd R ^a,b,c   Meyerson, Matthew ^a,b,c   Boehm, Jesse S ^b   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; HEAT SHOCK PROTEIN 90; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; DNA LIBRARY; DNA SEQUENCE; ENZYME INHIBITION; EPISTASIS; EXOME; GAIN OF FUNCTION MUTATION; GENETIC VARIABILITY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM CELL; MOUSE; NONHUMAN; ONCOGENE; OPEN READING FRAME; PHENOTYPE; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG TUMOR; MUTATION; PROCEDURES; TUMOR CELL LINE; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HETEROGRAFTS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MICE; MUTATION; ONCOGENES; PHENOTYPE;

EID: 84979896267     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2017.11.008     Document Type: Erratum

References (49)

1. Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gerasimova, A., Bork, P., Kondrashov, A.S., Sunyaev, S.R., A method and server for predicting damaging missense mutations. Nat. Methods 7 (2010), 248–249.
2. Berger, A.H., Imielinski, M., Duke, F., Wala, J., Kaplan, N., Shi, G.X., Andres, D.A., Meyerson, M., Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene 33 (2014), 4418–4423.
3. Berns, K., Hijmans, E.M., Mullenders, J., Brummelkamp, T.R., Velds, A., Heimerikx, M., Kerkhoven, R.M., Madiredjo, M., Nijkamp, W., Weigelt, B., et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428 (2004), 431–437.
4. Boehm, J.S., Zhao, J.J., Yao, J., Kim, S.Y., Firestein, R., Dunn, I.F., Sjostrom, S.K., Garraway, L.A., Weremowicz, S., Richardson, A.L., et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129 (2007), 1065–1079.
5. Bric, A., Miething, C., Bialucha, C.U., Scuoppo, C., Zender, L., Krasnitz, A., Xuan, Z., Zuber, J., Wigler, M., Hicks, J., et al. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 16 (2009), 324–335.
6. Davoli, T., Xu, A.W., Mengwasser, K.E., Sack, L.M., Yoon, J.C., Park, P.J., Elledge, S.J., Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell 155 (2013), 948–962.
7. Dunn, G.P., Cheung, H.W., Agarwalla, P.K., Thomas, S., Zektser, Y., Karst, A.M., Boehm, J.S., Weir, B.A., Berlin, A.M., Zou, L., et al. In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc. Natl. Acad. Sci. USA 111 (2014), 1102–1107.
8. Ebert, B.L., Pretz, J., Bosco, J., Chang, C.Y., Tamayo, P., Galili, N., Raza, A., Root, D.E., Attar, E., Ellis, S.R., et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 451 (2008), 335–339.
9. Emery, C.M., Vijayendran, K.G., Zipser, M.C., Sawyer, A.M., Niu, L., Kim, J.J., Hatton, C., Chopra, R., Oberholzer, P.A., Karpova, M.B., et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl. Acad. Sci. USA 106 (2009), 20411–20416.
10. Frampton, G.M., Fichtenholtz, A., Otto, G.A., Wang, K., Downing, S.R., He, J., Schnall-Levin, M., White, J., Sanford, E.M., An, P., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 31 (2013), 1023–1031.
11. Frohling, S., Scholl, C., Levine, R.L., Loriaux, M., Boggon, T.J., Bernard, O.A., Berger, R., Dohner, H., Dohner, K., Ebert, B.L., et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 12 (2007), 501–513.
12. Greulich, H., Chen, T.H., Feng, W., Janne, P.A., Alvarez, J.V., Zappaterra, M., Bulmer, S.E., Frank, D.A., Hahn, W.C., Sellers, W.R., et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med., 2, 2005, e313.
13. Hast, B.E., Cloer, E.W., Goldfarb, D., Li, H., Siesser, P.F., Yan, F., Walter, V., Zheng, N., Hayes, D.N., Major, M.B., Cancer-derived mutations in KEAP1 impair NRF2 degradation but not ubiquitination. Cancer Res. 74 (2014), 808–817.
14. Heidorn, S.J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J.S., Springer, C.J., Pritchard, C., et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140 (2010), 209–221.
15. Imielinski, M., Berger, A.H., Hammerman, P.S., Hernandez, B., Pugh, T.J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150 (2012), 1107–1120.
16. Imielinski, M., Greulich, H., Kaplan, B., Araujo, L., Amann, J., Horn, L., Schiller, J., Villalona-Calero, M.A., Meyerson, M., Carbone, D.P., Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J. Clin. Invest. 124 (2014), 1582–1586.
17. Jaramillo, M.C., Zhang, D.D., The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 27 (2013), 2179–2191.
18. Johannessen, C.M., Johnson, L.A., Piccioni, F., Townes, A., Frederick, D.T., Donahue, M.K., Narayan, R., Flaherty, K.T., Wargo, J.A., Root, D.E., et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 504 (2013), 138–142.
19. Kilpivaara, O., Aaltonen, L.A., Diagnostic cancer genome sequencing and the contribution of germline variants. Science 339 (2013), 1559–1562.
20. Kim, E., Ilic, N., Shrestha, Y., Zou, L., Kamburov, A., Zhu, C., Yang, X., Lubonja, R., Tran, N., Nguyen, C., et al. Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles. Cancer Discov. 6 (2016), 714–726.
21. Kitzman, J.O., Starita, L.M., Lo, R.S., Fields, S., Shendure, J., Massively parallel single-amino-acid mutagenesis. Nat. Methods 12 (2015), 203–206 204 p following 206.
22. Kwak, E.L., Bang, Y.J., Camidge, D.R., Shaw, A.T., Solomon, B., Maki, R.G., Ou, S.H., Dezube, B.J., Janne, P.A., Costa, D.B., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363 (2010), 1693–1703.
23. Lamb, J., Crawford, E.D., Peck, D., Modell, J.W., Blat, I.C., Wrobel, M.J., Lerner, J., Brunet, J.P., Subramanian, A., Ross, K.N., et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313 (2006), 1929–1935.
24. Lawrence, M.S., Stojanov, P., Polak, P., Kryukov, G.V., Cibulskis, K., Sivachenko, A., Carter, S.L., Stewart, C., Mermel, C.H., Roberts, S.A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499 (2013), 214–218.
25. Lawrence, M.S., Stojanov, P., Mermel, C.H., Robinson, J.T., Garraway, L.A., Golub, T.R., Meyerson, M., Gabriel, S.B., Lander, E.S., Getz, G., Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505 (2014), 495–501.
26. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004), 2129–2139.
27. Malhotra, D., Portales-Casamar, E., Singh, A., Srivastava, S., Arenillas, D., Happel, C., Shyr, C., Wakabayashi, N., Kensler, T.W., Wasserman, W.W., et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 38 (2010), 5718–5734.
28. Melnikov, A., Rogov, P., Wang, L., Gnirke, A., Mikkelsen, T.S., Comprehensive mutational scanning of a kinase in vivo reveals substrate-dependent fitness landscapes. Nucleic Acids Res., 42, 2014, e112.
29. Ng, P.C., Henikoff, S., SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 31 (2003), 3812–3814.
30. Oxnard, G.R., Lo, P.C., Nishino, M., Dahlberg, S.E., Lindeman, N.I., Butaney, M., Jackman, D.M., Johnson, B.E., Janne, P.A., Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J. Thorac. Oncol. 8 (2013), 179–184.
31. Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004), 1497–1500.
32. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101 (2004), 13306–13311.
33. Parnas, O., Jovanovic, M., Eisenhaure, T.M., Herbst, R.H., Dixit, A., Ye, C.J., Przybylski, D., Platt, R.J., Tirosh, I., Sanjana, N.E., et al. A genome-wide CRISPR screen in primary immune cells to dissect regulatory networks. Cell 162 (2015), 675–686.
34. Peck, D., Crawford, E.D., Ross, K.N., Stegmaier, K., Golub, T.R., Lamb, J., A method for high-throughput gene expression signature analysis. Genome Biol., 7, 2006, R61.
35. Polak, P., Karlic, R., Koren, A., Thurman, R., Sandstrom, R., Lawrence, M.S., Reynolds, A., Rynes, E., Vlahovicek, K., Stamatoyannopoulos, J.A., et al. Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature 518 (2015), 360–364.
36. Reva, B., Antipin, Y., Sander, C., Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res., 39, 2011, e118.
37. Roychowdhury, S., Iyer, M.K., Robinson, D.R., Lonigro, R.J., Wu, Y.M., Cao, X., Kalyana-Sundaram, S., Sam, L., Balbin, O.A., Quist, M.J., et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci. Transl. Med., 3, 2011, 111ra121.
38. Sahni, N., Yi, S., Taipale, M., Fuxman Bass, J.I., Coulombe-Huntington, J., Yang, F., Peng, J., Weile, J., Karras, G.I., Wang, Y., et al. Widespread macromolecular interaction perturbations in human genetic disorders. Cell 161 (2015), 647–660.
39. Sawey, E.T., Chanrion, M., Cai, C., Wu, G., Zhang, J., Zender, L., Zhao, A., Busuttil, R.W., Yee, H., Stein, L., et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell 19 (2011), 347–358.
40. Shalem, O., Sanjana, N.E., Hartenian, E., Shi, X., Scott, D.A., Mikkelsen, T.S., Heckl, D., Ebert, B.L., Root, D.E., Doench, J.G., et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343 (2014), 84–87.
41. Sharifnia, T., Rusu, V., Piccioni, F., Bagul, M., Imielinski, M., Cherniack, A.D., Pedamallu, C.S., Wong, B., Wilson, F.H., Garraway, L.A., et al. Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proc. Natl. Acad. Sci. USA 111 (2014), 18661–18666.
42. Shaw, A.T., Ou, S.H., Bang, Y.J., Camidge, D.R., Solomon, B.J., Salgia, R., Riely, G.J., Varella-Garcia, M., Shapiro, G.I., Costa, D.B., et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med. 371 (2014), 1963–1971.
43. Stratton, M.R., Campbell, P.J., Futreal, P.A., The cancer genome. Nature 458 (2009), 719–724.
44. Taylor, J.C., Martin, H.C., Lise, S., Broxholme, J., Cazier, J.B., Rimmer, A., Kanapin, A., Lunter, G., Fiddy, S., Allan, C., et al. Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nat. Genet. 47 (2015), 717–726.
45. TCGA, Comprehensive molecular profiling of lung adenocarcinoma. Nature 511 (2014), 543–550.
46. Van Allen, E.M., Wagle, N., Stojanov, P., Perrin, D.L., Cibulskis, K., Marlow, S., Jane-Valbuena, J., Friedrich, D.C., Kryukov, G., Carter, S.L., et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat. Med. 20 (2014), 682–688.
47. Wagle, N., Berger, M.F., Davis, M.J., Blumenstiel, B., Defelice, M., Pochanard, P., Ducar, M., Van Hummelen, P., Macconaill, L.E., Hahn, W.C., et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2 (2012), 82–93.
48. Wilson, F.H., Johannessen, C.M., Piccioni, F., Tamayo, P., Kim, J.W., Van Allen, E.M., Corsello, S.M., Capelletti, M., Calles, A., Butaney, M., et al. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell 27 (2015), 397–408.
49. Zender, L., Xue, W., Zuber, J., Semighini, C.P., Krasnitz, A., Ma, B., Zender, P., Kubicka, S., Luk, J.M., Schirmacher, P., et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135 (2008), 852–864.